Erythrocytosis: The HIF pathway in control

Blood

Volumn 122, Issue 7, 2013, Pages 1122-1128

  Franke, Kristin ^a   Gassmann, Max ^b,c   Wielockx, Ben ^a,d  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

^d CENTER FOR REGENERATIVE THERAPIES DRESDEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; ERYTHROPOIETIN; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 2ALPHA; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROLYL HYDROXYLASE DOMAIN PROTEIN 2; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN; HYPOXIA INDUCIBLE FACTOR 1;

ANEMIA; ERYTHROCYTE; ERYTHROCYTOSIS; ERYTHROPOIESIS; GENETIC TRANSCRIPTION; HOMEOSTASIS; HUMAN; MOLECULAR BIOLOGY; MOLECULAR PATHOLOGY; NONHUMAN; OXYGEN SENSING; POINT MUTATION; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; METABOLISM; PATHOLOGY; POLYCYTHEMIA;

ANIMALS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; POLYCYTHEMIA; SIGNAL TRANSDUCTION;

EID: 84887130699     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-01-478065     Document Type: Review

References (100)

1. Jourdanet D. Influence de la Pression de L'air sur la Vie de L'homme. Paris: Masson; 1875.
2. Miyake T, Kung CK, Goldwasser E. Purification of human erythropoietin. J Biol Chem. 1977; 252(15):5558-5564.
3. Jacobs K, Shoemaker C, Rudersdorf R, et al. Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature. 1985;313(6005):806-810.
4. Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol. 1992;12(12):5447-5454.
5. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loophelix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA. 1995;92(12): 5510-5514.
6. Wang GL, Semenza GL. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci USA. 1993;90(9):4304-4308.
7. Firth JD, Ebert BL, Pugh CW, Ratcliffe PJ. Oxygen-regulated control elements in the phosphoglycerate kinase 1 and lactate dehydrogenase A genes: similarities with the erythropoietin 39 enhancer. Proc Natl Acad Sci USA. 1994;91(14):6496-6500.
8. Nagao M, Ebert BL, Ratcliffe PJ, Pugh CW. Drosophila melanogaster SL2 cells contain a hypoxically inducible DNA binding complex which recognises mammalian HIF-binding sites. FEBS Lett. 1996;387(2-3):161-166.
9. Jacobson LO, Goldwasser E, Fried W, Plzak L. Role of the kidney in erythropoiesis. Nature. 1957;179(4560):633-634.
10. Koury ST, Bondurant MC, Koury MJ. Localization of erythropoietin synthesizing cells in murine kidneys by in situ hybridization. Blood. 1988;71(2):524-527.
11. Koury ST, Koury MJ, Bondurant MC, Caro J, Graber SE. Quantitation of erythropoietinproducing cells in kidneys of mice by in situ hybridization: correlation with hematocrit, renal erythropoietin mRNA, and serum erythropoietin concentration. Blood. 1989;74(2):645-651.
12. Bachmann S, Le Hir M, Eckardt KU. Colocalization of erythropoietin mRNA and ecto-59-nucleotidase immunoreactivity in peritubular cells of rat renal cortex indicates that fibroblasts produce erythropoietin. J Histochem Cytochem. 1993;41(3):335-341.
13. Maxwell PH, Osmond MK, Pugh CW, et al. Identification of the renal erythropoietinproducing cells using transgenic mice. Kidney Int. 1993;44(5):1149-1162.
14. Obara N, Suzuki N, Kim K, Nagasawa T, Imagawa S, Yamamoto M. Repression via the GATA box is essential for tissue-specific erythropoietin gene expression. Blood. 2008; 111(10):5223-5232.
15. Marti HH, Wenger RH, Rivas LA, et al. Erythropoietin gene expression in human, monkey and murine brain. Eur J Neurosci. 1996; 8(4):666-676.
16. Weidemann A, Kerdiles YM, Knaup KX, et al. The glial cell response is an essential component of hypoxia-induced erythropoiesis in mice. J Clin Invest. 2009;119(11):3373-3383.
17. Sakanaka M, Wen TC, Matsuda S, et al. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci USA. 1998;95(8):4635-4640.
18. Soliz J, Joseph V, Soulage C, et al. Erythropoietin regulates hypoxic ventilation in mice by interacting with brainstem and carotid bodies. J Physiol. 2005;568(Pt 2):559-571.
19. Miskowiak K, Inkster B, Selvaraj S, Wise R, Goodwin GM, Harmer CJ. Erythropoietin improves mood and modulates the cognitive and neural processing of emotion 3 days post administration. Neuropsychopharmacology. 2008;33(3):611-618.
20. Richmond TD, Chohan M, Barber DL. Turning cells red: signal transduction mediated by erythropoietin. Trends Cell Biol. 2005;15(3): 146-155.
21. Hattangadi SM, Wong P, Zhang L, Flygare J, Lodish HF. From stem cell to red cell: regulation of erythropoiesis at multiple levels by multiple proteins, RNAs, and chromatin modifications. Blood. 2011;118(24):6258-6268.
22. Bauer A, Tronche F, Wessely O, et al. The glucocorticoid receptor is required for stress erythropoiesis. Genes Dev. 1999;13(22): 2996-3002.
23. Broudy VC, Lin NL, Priestley GV, Nocka K, Wolf NS. Interaction of stem cell factor and its receptor c-kit mediates lodgment and acute expansion of hematopoietic cells in the murine spleen. Blood. 1996;88(1):75-81.
24. Lenox LE, Perry JM, Paulson RF. BMP4 and Madh5 regulate the erythroid response to acute anemia. Blood. 2005;105(7):2741-2748.
25. Ramos P, Casu C, Gardenghi S, et al. Macrophages support pathological erythropoiesis in polycythemia vera and b-thalassemia. Nat Med. 2013;19(4):437-445.
26. Jewell UR, Kvietikova I, Scheid A, Bauer C, Wenger RH, Gassmann M. Induction of HIF-1alpha in response to hypoxia is instantaneous. FASEB J. 2001;15(7):1312-1314.
27. Fandrey J, Gorr TA, Gassmann M. Regulating cellular oxygen sensing by hydroxylation. Cardiovasc Res. 2006;71(4):642-651.
28. Xia X, Lemieux ME, Li W, et al. Integrative analysis of HIF binding and transactivation reveals its role in maintaining histone methylation homeostasis. Proc Natl Acad Sci USA. 2009;106(11):4260-4265.
29. Schödel J, Oikonomopoulos S, Ragoussis J, Pugh CW, Ratcliffe PJ, Mole DR. High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq. Blood. 2011;117(23):e207-e217.
30. Ivan M, Kondo K, Yang H, et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science. 2001;292(5516):464-468.
31. Jaakkola P, Mole DR, Tian YM, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 2001;292(5516): 468-472.
32. Epstein AC, Gleadle JM, McNeill LA, et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell. 2001;107(1): 43-54.
33. Berra E, Benizri E, Ginouvès A, Volmat V, Roux D, Pouysségur J. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO J. 2003; 22(16):4082-4090.
34. Oehme F, Ellinghaus P, Kolkhof P, et al. Overexpression of PH-4, a novel putative proline 4-hydroxylase, modulates activity of hypoxiainducible transcription factors. Biochem Biophys Res Commun. 2002;296(2):343-349.
35. Wiesener MS, Jürgensen JS, Rosenberger C, et al. Widespread hypoxia-inducible expression of HIF-2alpha in distinct cell populations of different organs. FASEB J. 2003;17(2):271-273.
36. Hu C-J, Wang L-Y, Chodosh LA, Keith B, Simon MC. Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol Cell Biol. 2003;23(24): 9361-9374.
37. van Patot MC, Gassmann M. Hypoxia: adapting to high altitude by mutating EPAS-1, the gene encoding HIF-2a. High Alt Med Biol. 2011;12(2): 157-167.
38. Branco-Price C, Zhang N, Schnelle M, et al. Endothelial cell HIF-1a and HIF-2a differentially regulate metastatic success. Cancer Cell. 2012; 21(1):52-65.
39. Raval RR, Lau KW, Tran MGB, et al. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol. 2005;25(13): 5675-5686.
40. Petrella BL, Lohi J, Brinckerhoff CE. Identification of membrane type-1 matrix metalloproteinase as a target of hypoxiainducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma. Oncogene. 2005;24(6): 1043-1052.
41. Covello KL, Kehler J, Yu H, et al. HIF-2alpha regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth. Genes Dev. 2006;20(5):557-570.
42. Chen F, Zhang W, Liang Y, et al. Transcriptome and network changes in climbers at extreme altitudes. PLoS ONE. 2012;7(2):e31645.
43. Sergeyeva A, Gordeuk VR, Tokarev YN, Sokol L, Prchal JF, Prchal JT. Congenital polycythemia in Chuvashia. Blood. 1997;89(6):2148-2154.
44. Ang SO, Chen H, Gordeuk VR, et al. Endemic polycythemia in Russia: mutation in the VHL gene. Blood Cells Mol Dis. 2002;28(1):57-62.
45. Ang SO, Chen H, Hirota K, et al. Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat Genet. 2002;32(4): 614-621.
46. Russell RC, Sufan RI, Zhou B, et al. Loss of JAK2 regulation via a heterodimeric VHLSOCS1 E3 ubiquitin ligase underlies Chuvash polycythemia. Nat Med. 2011;17(7):845-853.
47. Bushuev VI, Miasnikova GY, Sergueeva AI, et al. Endothelin-1, vascular endothelial growth factor and systolic pulmonary artery pressure in patients with Chuvash polycythemia. Haematologica. 2006;91(6):744-749.
48. Gordeuk VR, Sergueeva AI, Miasnikova GY, et al. Congenital disorder of oxygen sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors. Blood. 2004;103(10):3924-3932.
49. Sable CA, Aliyu ZY, Dham N, et al. Pulmonary artery pressure and iron deficiency in patients with upregulation of hypoxia sensing due to homozygous VHL(R200W) mutation (Chuvash polycythemia). Haematologica. 2012;97(2): 193-200.
50. Gordeuk VR, Prchal JT. Vascular complications in Chuvash polycythemia. Semin Thromb Hemost. 2006;32(3):289-294.
51. Liu X, Hao L, Zhang S, et al. Genetic repression of mouse VEGF expression regulates coagulation cascade. IUBMB Life. 2010;62(11): 819-824.
52. Sergueeva AI, Miasnikova GY, Okhotin DJ, et al. Elevated homocysteine, glutathione and cysteinylglycine concentrations in patients homozygous for the Chuvash polycythemia VHL mutation. Haematologica. 2008;93(2):279-282.
53. Perrotta S, Nobili B, Ferraro M, et al. Von Hippel-Lindau-dependent polycythemia is endemic on the island of Ischia: identification of a novel cluster. Blood. 2006;107(2):514-519.
54. Liu E, Percy MJ, Amos CI, et al. The worldwide distribution of the VHL 598C.T mutation indicates a single founding event. Blood. 2004; 103(5):1937-1940.
55. Lee FS, Percy MJ. The HIF pathway and erythrocytosis. Annu Rev Pathol. 2011;6: 165-192.
56. Bond J, Gale DP, Connor T, et al. Dysregulation of the HIF pathway due to VHL mutation causing severe erythrocytosis and pulmonary arterial hypertension. Blood. 2011;117(13):3699-3701.
57. Lanikova L, Lorenzo F, Yang C, Vankayalapati H, Drachtman R, Divoky V, Prchal JT. Novel homozygous VHL mutation in exon 2 is associated with congenital polycythemia but not with cancer. Blood. 2013;121(19):3918-3924.
58. Tomasic NL, Piterkova L, Huff C, et al. The phenotype of polycythemia due to Croatian homozygous VHL (571C.G:H191D) mutation is different from that of Chuvash polycythemia (VHL 598C.T:R200W). Haematologica. 2013; 98(4):560-567.
59. Pastore Y, Jedlickova K, Guan Y, et al. Mutations of von Hippel-Lindau tumorsuppressor gene and congenital polycythemia. Am J Hum Genet. 2003;73(2):412-419.
60. Nordstrom-O'Brien M, van der Luijt RB, van Rooijen E, et al. Genetic analysis of von Hippel-Lindau disease. Hum Mutat. 2010;31(5): 521-537.
61. Albiero E, Ruggeri M, Fortuna S, et al. Analysis of the oxygen sensing pathway genes in familial chronic myeloproliferative neoplasms and identification of a novel EGLN1 germ-line mutation. Br J Haematol. 2011;153(3):405-408.
62. Albiero E, Ruggeri M, Fortuna S, et al. Isolated erythrocytosis: study of 67 patients and identification of three novel germ-line mutations in the prolyl hydroxylase domain protein 2 (PHD2) gene. Haematologica. 2012;97(1): 123-127.
63. Ladroue C, Hoogewijs D, Gad S, et al. Distinct deregulation of the hypoxia inducible factor by PHD2 mutants identified in germline DNA of patients with polycythemia. Haematologica. 2012;97(1):9-14.
64. Percy MJ, Zhao Q, Flores A, et al. A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis. Proc Natl Acad Sci USA. 2006; 103(3):654-659.
65. Pappalardi MB, Martin JD, Jiang Y, et al. Biochemical characterization of human prolyl hydroxylase domain protein 2 variants associated with erythrocytosis. Biochemistry. 2008;47(43):11165-11167.
66. Percy MJ, Furlow PW, Beer PA, Lappin TRJ, McMullin MF, Lee FS. A novel erythrocytosisassociated PHD2 mutation suggests the location of a HIF binding groove. Blood. 2007;110(6): 2193-2196.
67. Al-Sheikh M, Moradkhani K, Lopez M, Wajcman H, Préhu C. Disturbance in the HIF-1alpha pathway associated with erythrocytosis: further evidences brought by frameshift and nonsense mutations in the prolyl hydroxylase domain protein 2 (PHD2) gene. Blood Cells Mol Dis. 2008;40(2):160-165.
68. Ladroue C, Carcenac R, Leporrier M, et al. PHD2 mutation and congenital erythrocytosis with paraganglioma. N Engl J Med. 2008; 359(25):2685-2692.
69. Percy MJ, Furlow PW, Lucas GS, et al. A gainof-function mutation in the HIF2A gene in familial erythrocytosis. N Engl J Med. 2008;358(2): 162-168.
70. Percy MJ, Chung YJ, Harrison C, et al. Two new mutations in the HIF2A gene associated with erythrocytosis. Am J Hematol. 2012;87(4): 439-442.
71. Beall CM, Cavalleri GL, Deng L, et al. Natural selection on EPAS1 (HIF2alpha) associated with low hemoglobin concentration in Tibetan highlanders. Proc Natl Acad Sci USA. 2010; 107(25):11459-11464.
72. Simonson TS, Yang Y, Huff CD, et al. Genetic evidence for high-altitude adaptation in Tibet. Science. 2010;329(5987):72-75.
73. Lorenzo FR, Yang C, Ng Tang Fui M, et al. A novel EPAS1/HIF2A germline mutation in a congenital polycythemia with paraganglioma. J Mol Med (Berl). 2013;91(4):507-512.
74. Zhuang Z, Yang C, Lorenzo F, et al. Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia. N Engl J Med. 2012;367(10):922-930.
75. Yang C, Sun MG, Matro J, et al. Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas. Blood. 2013;121(13): 2563-2566.
76. Comino-Méndez I, de Cubas AA, Bernal C, et al. Tumoral EPAS1 (HIF2A) mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis. Hum Mol Genet. 2013;22(11):2169-2176.
77. Täieb D, Yang C, Delenne B, et al. First Report of Bilateral Pheochromocytoma in the Clinical Spectrum of HIF2A-Related Polycythemia-Paraganglioma Syndrome. J Clin Endocrinol Metab. 2013;98(5):E908-E913.
78. Toledo RA, Qin Y, Srikantan S, et al. In vivo and in vitro oncogenic effects of HIF2A mutations in pheochromocytomas and paragangliomas. Endocr Relat Cancer. 2013;20(3):349-359.
79. Iyer NV, Kotch LE, Agani F, et al. Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev. 1998;12(2):149-162.
80. Ryan HE, Lo J, Johnson RS. HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J. 1998;17(11): 3005-3015.
81. Scortegagna M, Ding K, Zhang Q, et al. HIF-2alpha regulates murine hematopoietic development in an erythropoietin-dependent manner. Blood. 2005;105(8):3133-3140.
82. Gruber M, Hu C-J, Johnson RS, Brown EJ, Keith B, Simon MC. Acute postnatal ablation of Hif-2alpha results in anemia. Proc Natl Acad Sci USA. 2007;104(7):2301-2306.
83. Kapitsinou PP, Liu Q, Unger TL, et al. Hepatic HIF-2 regulates erythropoietic responses to hypoxia in renal anemia. Blood. 2010;116(16): 3039-3048.
84. Paliege A, Rosenberger C, Bondke A, et al. Hypoxia-inducible factor-2alpha-expressing interstitial fibroblasts are the only renal cells that express erythropoietin under hypoxia-inducible factor stabilization. Kidney Int. 2010;77(4): 312-318.
85. Rankin EB, Biju MP, Liu Q, et al. Hypoxiainducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo. J Clin Invest. 2007;117(4): 1068-1077.
86. Tan Q, Kerestes H, Percy MJ, et al. Erythrocytosis and Pulmonary Hypertension in a Mouse Model of Human HIF2A Gain-of-Function Mutation [published online ahead of print May 2, 2013]. J Biol Chem. doi:10.1182/jbc. M112.444059.
87. Takeda K, Ho VC, Takeda H, Duan L-J, Nagy A, Fong G-H. Placental but not heart defects are associated with elevated hypoxia-inducible factor alpha levels in mice lacking prolyl hydroxylase domain protein 2. Mol Cell Biol. 2006;26(22):8336-8346.
88. Minamishima YA, Moslehi J, Bardeesy N, Cullen D, Bronson RT, Kaelin WG Jr. Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure. Blood. 2008;111(6):3236-3244.
89. Takeda K, Aguila HL, Parikh NS, et al. Regulation of adult erythropoiesis by prolyl hydroxylase domain proteins. Blood. 2008; 111(6):3229-3235.
90. Minamishima YA, Moslehi J, Padera RF, Bronson RT, Liao R, Kaelin WG Jr. A feedback loop involving the Phd3 prolyl hydroxylase tunes the mammalian hypoxic response in vivo. Mol Cell Biol. 2009;29(21):5729-5741.
91. Minamishima YA, Kaelin WG Jr. Reactivation of hepatic EPO synthesis in mice after PHD loss. Science. 2010;329(5990):407.
92. Franke K, Kalucka J, Mamlouk S, et al. HIF-1a is a protective factor in conditional PHD2-deficient mice suffering from severe HIF-2a-induced excessive erythropoiesis. Blood. 2013;121(8): 1436-1445.
93. Percy MJ, Beer PA, Campbell G, et al. Novel exon 12 mutations in the HIF2A gene associated with erythrocytosis. Blood. 2008;111(11): 5400-5402.
94. Gnarra JR, Ward JM, Porter FD, et al. Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice. Proc Natl Acad Sci USA. 1997;94(17):9102-9107.
95. Haase VH, Glickman JN, Socolovsky M, Jaenisch R. Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor. Proc Natl Acad Sci USA. 2001;98(4):1583-1588.
96. Rankin EB, Higgins DF, Walisser JA, Johnson RS, Bradfield CA, Haase VH. Inactivation of the arylhydrocarbon receptor nuclear translocator (Arnt) suppresses von Hippel-Lindau diseaseassociated vascular tumors in mice. Mol Cell Biol. 2005;25(8):3163-3172.
97. Rankin EB, Wu C, Khatri R, et al. The HIF signaling pathway in osteoblasts directly modulates erythropoiesis through the production of EPO. Cell. 2012;149(1):63-74.
98. Hickey MM, Lam JC, Bezman NA, Rathmell WK, Simon MC. von Hippel-Lindau mutation in mice recapitulates Chuvash polycythemia via hypoxiainducible factor-2alpha signaling and splenic erythropoiesis. J Clin Invest. 2007;117(12): 3879-3889.
99. Mazzone M, Dettori D, Leite de Oliveira R, et al. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell. 2009;136(5): 839-851.
100. Scortegagna M, Ding K, Oktay Y, et al. Multiple organ pathology, metabolic abnormalities and impaired homeostasis of reactive oxygen species in Epas1-/-mice. Nat Genet. 2003; 35(4):331-340.